MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Dermira Company Profile (NASDAQ:DERM)

Consensus Ratings for Dermira (NASDAQ:DERM) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $43.17 (57.77% upside)

Analysts' Ratings History for Dermira (NASDAQ:DERM)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016Needham & Company LLCReiterated RatingBuy$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Leerink SwannReiterated RatingBuy$46.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016WedbushBoost Price TargetOutperform$42.00 -> $46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Citigroup Inc.Lower Price TargetBuy$42.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/19/2015Cowen and CompanyInitiated CoverageOutperform$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2015GuggenheimBoost Price TargetBuy$22.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Dermira (NASDAQ:DERM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/10/2016Q1($0.94)($0.95)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q4($0.95)($1.04)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q3($0.77)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q2($0.81)($0.69)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q1($0.65)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2015Q4($0.59)($0.29)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Dermira (NASDAQ:DERM)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($1.00)($1.00)($1.00)
Q2 20161($0.96)($0.96)($0.96)
Q3 20161($0.72)($0.72)($0.72)
Q4 20161($0.97)($0.97)($0.97)
(Data provided by Zacks Investment Research)
Dividend History for Dermira (NASDAQ:DERM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Dermira (NASDAQ:DERM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/23/2016Luis C PenaInsiderSell10,000$30.01$300,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2016Luis C PenaInsiderSell10,000$29.47$294,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2016Christopher M GriffithVPSell4,405$30.16$132,854.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Eugene A BauerInsiderSell2,500$31.65$79,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Thomas G WiggansCEOSell11,000$31.57$347,270.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Eugene A BauerInsiderSell2,500$25.09$62,725.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Thomas G WiggansCEOSell9,000$25.11$225,990.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Eugene A BauerInsiderSell2,500$20.84$52,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Thomas G WiggansCEOSell7,000$20.69$144,830.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Eugene A BauerInsiderSell2,500$22.55$56,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Thomas G WiggansCEOSell7,000$22.57$157,990.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Eugene A BauerInsiderSell2,500$27.26$68,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Thomas G WiggansCEOSell9,000$27.25$245,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Eugene A BauerInsiderSell2,500$33.17$82,925.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Thomas G WiggansCEOSell11,000$33.17$364,870.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Eugene A BauerInsiderSell2,500$29.65$74,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Eugene A BauerInsiderSell2,500$27.82$69,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Eugene A BauerInsiderSell2,500$22.87$57,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Eugene A BauerInsiderSell22,500$28.05$631,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2014Matthew K FustDirectorBuy6,000$16.77$100,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014Bay City Capital LlcDirectorBuy69,112$16.00$1,105,792.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Dermira (NASDAQ:DERM)
DateHeadline
06/27/16 03:34 PMNext Weeks Broker Price Targets For Dermira, Inc. (NASDAQ:DERM) - Fiscal Standard
06/27/16 03:34 PMHow Many Dermira Inc (NASDAQ:DERM)'s Analysts Are Bearish? - Press Telegraph
06/24/16 10:19 AMForm 4 Dermira, Inc. For: Jun 21 Filed by: CRAVES FRED B - StreetInsider.com
06/23/16 02:30 PMLooking At Post-Earnings Stock Movement: Dermira, Inc. (NASDAQ:DERM) - iStreetWire
06/23/16 02:30 PMStrong Buy Calls Count For Dermira, Inc. (NASDAQ:DERM) At 2 - Investor Newswire
06/22/16 08:49 PMDERMIRA, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
06/22/16 03:45 PMDermira, Inc. (NASDAQ:DERM) Current Analyst Ratings - Fiscal Standard
06/22/16 03:10 PMDERMIRA, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/20/16 03:30 PMDermira, Inc. (NASDAQ:DERM) Analyst Price Targets For The Coming Week - Fiscal Standard
06/16/16 07:56 AMTrend Of Rating Given To Dermira, Inc. (NASDAQ:DERM) - Investor Newswire
06/13/16 03:05 PMDermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares - [GlobeNewswire] - MENLO PARK, Calif., June 13, 2016-- Dermira, Inc., a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients ...
06/09/16 10:52 AMTrending Stock Analysis: Dermira, Inc. (NASDAQ:DERM) - News Oracle
06/09/16 10:52 AMAnalyst Rating Fluctuations to Observe: UnitedHealth Group Incorporated (NYSE:UNH) , Dermira, Inc. (NASDAQ:DERM) - Street Updates
06/08/16 08:22 PMPre-Market Investor's Watch List: Dermira Inc.(NASDAQ:DERM), AK Steel Holding Corporation(NYSE:AKS) - iStreetWire
06/08/16 08:22 PMDERMIRA INC. (NASDAQ:DERM) Financial Condition Compared to S&P 500 - CML News
06/08/16 03:09 PMDERMIRA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and -
06/08/16 06:08 AMDermira Prices $126 Million Public Offering of Common Stock - [at noodls] - MENLO PARK, Calif., June 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies ...
06/08/16 06:01 AM7:01 am Dermira prices 4.5 mln common stock offering at $28.00/share -
06/07/16 09:12 PMMaruho Co., Ltd. - Strategic SWOT Analysis Review - New Market Report
06/07/16 03:28 PMDermira Announces Proposed Public Offering of Common Stock - [at noodls] - MENLO PARK, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies ...
06/06/16 04:40 AMDrug for excessive armpit sweating succeeds in key studies
06/03/16 10:21 AMMedivation Inc (NASDAQ:MDVN) & Dermira Inc (NASDAQ:DERM) Healthcare Stocks in Focus - Wall Street 24
06/02/16 12:50 PMDermira (DERM) Stock Slumps Despite Favorable Trial Results -
06/02/16 12:17 PMMaker of sweaty armpit treatment sees shares slide -
06/02/16 09:40 AMDermira Inc (NASDAQ:DERM): A Slow Burner, But One To Watch - Market Exclusive - Market ExclusiveDermira Inc (NASDAQ:DERM): A Slow Burner, But One To WatchMarket ExclusiveDermira Inc (NASDAQ:DERM) just reported topline from its pivotal DRM04 trial. The trial investigated the efficacy of a condition called hyperhidrosis – a condition that affects more than 4 million individuals in the US. It's essentially an over ...Analysts At Needham Reiterated Dermira Inc (NASDAQ:DERM) As BuyRisers & FallersDermira Inc. (DERM) Is Climbing On Phase 3 Study ResultsRTT News3 Stocks to Watch on Thursday: Ciena Corporation (CIEN), Dermira Inc (DERM) and Joy Global Inc. (JOY)Investorplace.comLet Me Know About This -Market Digest -The Wall Street Transcriptall 18 news articles »
06/01/16 03:45 PMDermira Inc.: Dermira Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Trials for DRM04 in ... - The Wall Street Transcript - Reuters UKDermira Inc.: Dermira Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Trials for DRM04 in ...The Wall Street TranscriptMENLO PARK, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with ...Dermira's drug for excessive armpit sweating succeeds in key studiesChannel News Asiaall 2 news articles »
06/01/16 03:25 PMDermira Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Trials for DRM04 in Patients with Primary Axillary Hyperhidrosis - [at noodls] - MENLO PARK, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies ...
06/01/16 03:15 PMDermira's drug for excessive armpit sweating succeeds in key studies - [Reuters] - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the embarrassing, ...
05/31/16 03:39 PMDermira, Inc. (NASDAQ:DERM) Stock Update & Estimates - Stock Tick Tock - Dermira, Inc. (NASDAQ:DERM) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Dermira, Inc. (NASDAQ:DERM) to post earnings of $-0.96 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued around ...and more »
05/17/16 07:05 AMDermira (DERM) in Focus: Stock Gains 8.7% in Session -
05/11/16 04:07 PMDermira to Present Preclinical Data from DRM01 Acne Program at the Society for Investigative Dermatology 75th Annual Meeting - [at noodls] - MENLO PARK, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies ...
05/10/16 07:30 AMDermira Inc Conference Call To Discuss DRM01 Phase 2b Clinical Trial Results scheduled for 8:30 am ET today -
05/10/16 05:56 AMDERMIRA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
05/10/16 05:54 AMDermira reports 1Q loss -
05/10/16 05:48 AMDermira Reports First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - - Positive Topline Results for DRM01 Phase 2b Acne Trial Reported; Phase 3 Program Planning Underway - Announcement of Topline Results for DRM04 Phase 3 Hyperhidrosis Pivotal Trials Expected in Second ...
05/10/16 05:36 AMDERMIRA, INC. Files SEC form 10-Q, Quarterly Report -
05/10/16 05:28 AMDermira Announces Positive Topline Phase 2b Clinical Trial Results for DRM01 in Patients with Facial Acne Vulgaris - [at noodls] - - Safety and Efficacy Data Confirm Results from Previous Phase 2a Trial - DRM01 Phase 3 Clinical Program Planning Underway - Management to Host Webcast and Conference Call Today at 5:30 a.m. PT / 8:30 ...
02/26/16 11:57 AMWere Analysts Bullish Dermira Inc (NASDAQ:DERM) This Week? - Business Standard Tribune - Were Analysts Bullish Dermira Inc (NASDAQ:DERM) This Week?Business Standard TribuneOut of 5 analysts covering Dermira Inc (NASDAQ:DERM), 0 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Dermira Inc was the topic in 6 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Below is a list of ...
02/07/16 01:06 PMToday Dermira Inc Stock Rises - Sonoran Weekly Review - Today Dermira Inc Stock RisesSonoran Weekly ReviewThe stock of Dermira Inc (NASDAQ:DERM) is a huge mover today! The stock increased 1.66% or $0.43 during the last trading session, hitting $26.37. About 206,725 shares traded hands or 46.93% up from the average. Dermira Inc (NASDAQ:DERM) has ...
02/05/16 03:32 PMDERMIRA, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
02/04/16 01:33 PMGlobal Dermira Inc Market Share, Growth 2014 to 2022 - RD News Mag - Global Dermira Inc Market Share, Growth 2014 to 2022RD News MagAcuteMarketReports.com has announced the addition of “Global Dermira Inc Product Pipeline Review H1 2015 “Market Research Report to their Database. The ' Dermira Inc – Pipeline Review, H1 2015', provides an overview of the Dermira Inc's therapeutic ...and more »
02/04/16 06:00 AMDermira to Present at the Leerink Partners 5th Annual Global Healthcare Conference - [GlobeNewswire] - MENLO PARK, Calif., Feb. 04, 2016-- Dermira, Inc., a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients ...
02/03/16 01:02 PMCompany Shares of Dermira, Inc. (NASDAQ:DERM) Drops by -1.41% - Bull Report - Company Shares of Dermira, Inc. (NASDAQ:DERM) Drops by -1.41%Bull ReportDermira, Inc. (NASDAQ:DERM) has lost 1.41% during the past week and dropped 19.1% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 3.1%. Dermira, Inc. (NASDAQ:DERM) has ...
02/03/16 01:02 PMInsider Trade: Dermira Inc (NASDAQ:DERM)'s CEO & Chairman of the Board Thomas Wiggans Sold 9000 shares - fdanewsalert.com - Insider Trade: Dermira Inc (NASDAQ:DERM)'s CEO & Chairman of the Board Thomas Wiggans Sold 9000 sharesfdanewsalert.comIn a document that's filled with the U.S. SEC, it was made public that the CEO & Chairman of the Board of Dermira Inc Thomas Wiggans, an insider in focus, made sold via broker for 9,000 shares of the public firm, valued at $245,268 U.S. Dollars using ...Dermira Inc (DERM) CEO Thomas G. Wiggans Sells 9000 SharesIntercooler Financialall 2 news articles »
02/02/16 01:12 PMCommit To Buy Dermira At $22.50, Earn 17.5% Annualized Using Options - TheStreet.com - TheStreet.comCommit To Buy Dermira At $22.50, Earn 17.5% Annualized Using OptionsTheStreet.comInvestors eyeing a purchase of Dermira Inc (DERM) stock, but cautious about paying the going market price of $26.75/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in ...and more »
02/02/16 01:12 PMCommit To Buy Dermira At $22.50, Earn 17.5% Annualized Using Options - Investors eyeing a purchase of Dermira Inc (DERM) stock, but cautious about paying the going market price of $26.75/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in ...
01/29/16 12:57 PMForm SC 13G Dermira, Inc. Filed by: BlackRock Inc. - StreetInsider.com - Form SC 13G Dermira, Inc. Filed by: BlackRock Inc.StreetInsider.comVarious persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of DERMIRA INC. No one person's interest in the common stock of DERMIRA INC is more than five percent of ...and more »
01/27/16 12:20 PMAcne Vulgaris Pipeline Review 2015 - Research and Markets - Inc. Cosmo Pharmaceuticals S.p.A Delenex Therapeutics AG Deltanoid Pharmaceuticals Inc. DermaXon, LLC Dermira Inc. ELORAC, Inc. Ensol Biosciences Inc. Foamix Pharmaceuticals Ltd. Galderma S.A. GlaxoSmithKline Plc Helix BioMedix, Inc. Hovione FarmaCiencia ...
01/25/16 12:14 PMRecent Broker Updates On Dermira, Inc. (NASDAQ:DERM) - Risers & Fallers - Recent Broker Updates On Dermira, Inc. (NASDAQ:DERM)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Dermira, Inc. (NASDAQ:DERM). The latest broker reports which are currently outstanding on Monday 25th January state 3 analysts have a rating of “strong buy”, 2 analysts ...Company Shares of Dermira, Inc. (NASDAQ:DERM) Drops by -1.18%The Daily Roverall 2 news articles »
01/22/16 11:57 AMOff the Radar Dermira Targets a Billion Dollar Opportunity - Now and again we like to uncover an off the radar stock in biotech. Here’s one such case – Dermira, Inc. (NASDAQ:DERM). Dermira is a development stage biotech with a focus on (as its name suggests) dermatological conditions, Its current primary focus ...
About Dermira

Dermira logoDermira, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company's portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor, that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. DRM04 is a topical, small-molecule anticholinergic product for the treatment of hyperhidrosis. DRM01 is a topical, small-molecule sebum inhibitor for the treatment of acne.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: DERM
  • CUSIP:
Key Metrics:
  • Previous Close: $27.36
  • 50 Day Moving Average: $29.67
  • 200 Day Moving Average: $26.83
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $821.29M
  • Current Quarter EPS Consensus Estimate: $-3.51 EPS
Additional Links:
Dermira (NASDAQ:DERM) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha